Source: yahoo_news
Source ID: yahoo:77cb9ebfed5f1148e1336f4bceeb2f96:TRDA
URL: https://finance.yahoo.com/healthcare/articles/entrada-therapeutics-reports-second-quarter-110000613.html?.tsrc=rss
Symbol: (TRDA)
Published: 2026-08-05 07:00:00 EDT
Time precision: minute
Title: Entrada Therapeutics Reports Second Quarter 2026 Financial Results

-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc